{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:56:07Z","timestamp":1781207767490,"version":"3.54.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI158530"],"award-info":[{"award-number":["R01AI158530"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R21AI174159"],"award-info":[{"award-number":["R21AI174159"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Population pharmacokinetic (PK) models can be combined with Bayesian estimation to optimize dosing regimens. The impact of sample collection time on the accuracy and precision of Bayesian predictions was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from adult and pediatric patients were used to develop a cefepime population PK model for Bayesian prior use. Holdout data were used for model evaluation. Clinical dosing regimens in the latter cohort were used to conduct optimal sample-time analysis. The accuracy and precision of the Bayesian predictions were assessed as a function of infusion duration and the differences between the observed and optimal sampling times. Analyses were conducted using Pmetrics for R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      An allometrically scaled 2-compartment model was fitted (n = 71 patients, 685 observations). In the holdout group (n = 116 patients, 203 observations), the posterior Bayesian fit was acceptable (\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0.923; relative bias \u22123%; median absolute error, 11.2%; F20, 72%; and F30, 86%). Mid-interval sampling was the optimal 1-sample design for 11\/16 regimens. In the 2-sample design, a peak (8\/16 regimens) and trough (9\/16 regimens) approach was frequently optimal. The 2-sample design yields a lower Bayesian risk of misclassification. For 0.5-hour infusions, Bayesian predictions were similarly accurate but significantly more imprecise when samples were collected &gt;2 hour away from the optimal time versus within \u00b11 hour of the optimal time (\u0394RMSE: 8.98 mg\/L, 95% CI: 3.61\u201315.7 mg\/L). For 3 hours infusions, no significant differences in the accuracy or imprecision of the Bayesian predictions were noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The nonparametric cefepime population PK model fit as a Bayesian prior in the holdout group. The optimal timing of PK sample collection varied according to regimen type and infusion duration. The precision of Bayesian estimates was lower for 0.5-hour infusions when samples were collected further from the model-predicted regimen-specific optimal collection times.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001483","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:00:11Z","timestamp":1781204411000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Defining Optimal Sampling Strategies for Cefepime Model-Informed Precision Dosing"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4192-5229","authenticated-orcid":false,"given":"Adrian","family":"Valadez","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois;"},{"name":"Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Pan","sequence":"additional","affiliation":[{"name":"UVA Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Weslander","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R.","family":"Galvin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H.","family":"Hughes","sequence":"additional","affiliation":[{"name":"InsightRX, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Stephanie A.","family":"Hughes","sequence":"additional","affiliation":[{"name":"InsightRX, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fekade B.","family":"Sime","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, University of Queensland, Brisbane, Queensland, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Faculty of Health, Medicine and Behavioural Sciences, Frazer Institute, University of Queensland, Brisbane, Australia;"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia;"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia;"},{"name":"Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, UR UM 103, University of Montpellier, N\u00eemes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Kiel","sequence":"additional","affiliation":[{"name":"Indiana University, Indianapolis, Indiana;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Neely","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California;"},{"name":"Laboratory of Applied Pharmacokinetics and Bioinformatics, Saban Research Institute, Children's Hospital of Los Angeles, Los Angeles, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois;"},{"name":"Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, Illinois;"},{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois;"},{"name":"Departments of Pharmacology and Biomedical Sciences, College of Graduate Studies, Midwestern University, Downers Grove, Illinois; and"},{"name":"DoseMe, Chair Clinical of Advisory Board, Jupiter, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-5434","authenticated-orcid":false,"given":"Nathaniel J.","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois;"},{"name":"Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, Illinois;"},{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"suppl 1","key":"R1-20260611","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1007\/BF02389870","article-title":"Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens","volume":"12","author":"Craig","year":"1993","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R2-20260611","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother."},{"key":"R3-20260611","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"R4-20260611","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2015.06.002","article-title":"Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization","volume":"24","author":"Sime","year":"2015","journal-title":"Curr Opin Pharmacol."},{"key":"R5-20260611","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0000000000001293","article-title":"Multiple model optimal sampling promotes accurate vancomycin area-under-the-curve estimation using a single sample in critically ill children","volume":"47","author":"Downes","year":"2025","journal-title":"Ther Drug Monit."},{"key":"R6-20260611","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.01141-08","article-title":"Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia","volume":"53","author":"Nicasio","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20260611","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"R9-20260611","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/AAC.00032-15","article-title":"Achieving target voriconazole concentrations more accurately in children and adolescents","volume":"59","author":"Neely","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R10-20260611","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/pharmaceutics15051336","article-title":"Optimizing vancomycin therapy in critically ill children: a population pharmacokinetics study to inform vancomycin area under the curve estimation using novel biomarkers","volume":"15","author":"Downes","year":"2023","journal-title":"Pharmaceutics"},{"key":"R11-20260611","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20260611","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev."},{"key":"R13-20260611","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/FTD.0b013e3181f675c2","article-title":"Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients","volume":"32","author":"Delattre","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R14-20260611","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R16-20260611","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40262-015-0280-4","article-title":"Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring and patient care","volume":"54","author":"Jelliffe","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"R17-20260611","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10928-016-9498-5","article-title":"Experiment design for nonparametric models based on minimizing Bayes risk: application to voriconazole1","volume":"44","author":"Bayard","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R18-20260611","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-020-00873-3","article-title":"Development of population and Bayesian models for applied use in patients receiving cefepime","volume":"59","author":"Liu","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R19-20260611","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R20-20260611","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/pharmaceutics13010042","article-title":"An algorithm for nonparametric estimation of a multivariate mixing distribution with applications to population pharmacokinetics","volume":"13","author":"Yamada","year":"2020","journal-title":"Pharmaceutics"},{"key":"R21-20260611","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/psp4.12720","article-title":"Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients","volume":"10","author":"Hanafin","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R22-20260611","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bcp.12830","article-title":"External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients","volume":"81","author":"Zhao","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R23-20260611","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40262-023-01233-7","article-title":"External evaluation of population pharmacokinetic models for precision dosing: current state and knowledge gaps","volume":"62","author":"El Hassani","year":"2023","journal-title":"Clin Pharmacokinet."},{"key":"R24-20260611","doi-asserted-by":"crossref","first-page":"e0010423","DOI":"10.1128\/aac.00104-23","article-title":"Systematic evaluation of pharmacokinetic models for model-informed precision dosing of meropenem in critically ill patients undergoing continuous renal replacement therapy","volume":"67","author":"Schatz","year":"2023","journal-title":"Antimicrob Agents Chemother."},{"key":"R25-20260611","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R26-20260611","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01520-08","article-title":"Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs","volume":"53","author":"Goutelle","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R28-20260611","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00007691-200006000-00018","article-title":"Achieving target goals most precisely using nonparametric compartmental models and \u201cmultiple model\u201d design of dosage regimens","volume":"22","author":"Jelliffe","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R29-20260611","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R30-20260611","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-Lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:00:14Z","timestamp":1781204414000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001483","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"2025-12-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}